Genomic Biomarkers Predict Response/Resistance To Lenalidomide In Non-Del(5q) Myelodysplastic Syndromes

Lenalidomide (Len) is FDA approved for the treatment of patients (pts) with lower-risk, transfusion-dependent myelodysplastic syndromes (MDS) with deletion (5q). It is frequently used in lower-risk pts with non-del (5q) MDS, with a transfusion independence response rate of 27%. Identification of pts who may or may not respond to Len can prevent prolonged exposure to ineffective therapy, avoid toxicities, and decrease unnecessary costs. Clinical or genomic data have limited utility in predicting response/resistance to Len.